Corporate Governance

Governance

The composition of NervGen’s Board and Committees are as follows:

* indicates independent non-executive board member

Director	Board	Audit	Compensation	Nominating and Corporate Governance	Science

Brian Bayley*
Glenn Ives
Randall Kaye*
Mike Kelly
Neil Klompas*
Krista McKerracher*
Harold Punnett*
Adam Rogers
John Ruffolo*
Craig Thompson*

Governance Documents

Board of Directors Charter

Audit Committee Charter

Compensation Committee Charter

Nominating and Corporate Governance Committee Charter

Science Committee Charter

Code of Business Conduct and Ethics

Whistleblower Policy

NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Contact

112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4

Phone: (778) 731-1711
Email: info@nervgen.com

Subscribe for Updates